Trend of outcomes in renal transplant recipients with hepatitis B virus: a longitudinal analysis using a national database

doi:10.1016/j.transproceed.2013.11.053

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/19291

請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/19291

題名:	Trend of outcomes in renal transplant recipients with hepatitis B virus: a longitudinal analysis using a national database
作者:	SF, Tsai KH, Shu HC, Ho CY, Cheng CH, Lin SN, Chang MJ, Wu
貢獻者:	中山醫學大學
日期:	2014
上傳時間:	2018-06-22T04:47:57Z (UTC)
出版者:	Transplant Proc
ISSN:	0041-1345
摘要:	INTRODUCTION: Manifestations of hepatitis B virus (HBV) infection in renal transplant (RTx) recipients tend to be worse because of the higher viral load. RTx recipients with Asian heritage have a higher HBV infection rate and have unique characteristics. To date, no large-scale study on the outcomes of Asian RTx recipients has been conducted. Furthermore, there are few longitudinal studies comparing outcomes before and after availability of anti-HBV drugs. MATERIAL AND METHODS: We conducted a nationwide, population-based study to elucidate patient survival, graft survival, and hepatic outcome (incidence of hepatoma) in Asian RTx recipients. The study includes all RTx recipients in Taiwan from 1997 to 2006. Patients were divided into 2 groups according to HBV infection status to examine the effect of antiviral drug therapy. RESULTS: In all, 3826 RTx recipients were followed for a mean of 7.4 years, with a mean age of 43.7 years. There were no differences between the HBV and non-HBV groups in patient or graft survival rates. At 5 years after RTx, 89.2% of the patients were still alive and 84.5% RTx recipients were still dialysis free. In the era before anti-HBV drugs were available (1997-2001), patient survival in the HBV and non-HBV groups were similar (P = .614). This result can also be seen in the anti-HBV drug era, from 2002 to 2006 (P = .148). The unusual lack of a significant effect of drug anti-HBV administration on HBV-related mortality in RTx patients may be explained by the short duration of follow-up in the 2 eras. Another explanation may be the confounding effect of the different health status of RTx patients in the pre-anti-HBV drug era, when cardiovascular and infection-related mortality rates were considerably greater than HBV-related mortality rates. CONCLUSION: These results demonstrate that HBV is not a contraindication for RTx. Asian recipients with HBV can still achieve a similar graft outcome and survival rate compared with those of patients without HBV.
URI:	http://dx.doi.org/10.1016/j.transproceed.2013.11.053 https://ir.csmu.edu.tw:8080/ir/handle/310902500/19291
關聯:	Transplant Proc. 2014;46(2):578-82
顯示於類別:	[醫學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	198	檢視/開啟

檢視Licence

在CSMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....